Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Rhea-AI Summary

Lunai Bioworks (NASDAQ: LNAI) completed a $20.0 million Series B preferred issuance on May 1, 2026 to acquire CNS delivery and neurotherapeutic IP, adding a BBB‑crossing prodrug system and a nose‑to‑brain (N2B) delivery pathway.

The assets will be integrated into a wholly owned subsidiary to support Alzheimer's and other neurological programs, 505(b)(2) pathways, combination therapies, biodefense countermeasures, and potential partnerships. The company believes stockholders' equity exceeds the $2.5 million Nasdaq minimum and awaits the Panel's formal determination.

Positive

• Completed $20.0M Series B preferred issuance to acquire CNS IP
• Adds two complementary CNS delivery technologies: BBB prodrug and N2B
• Assets integrated into wholly owned IP subsidiary to centralize development
• Supports 505(b)(2) regulatory pathways for reformulated/repurposed therapeutics

Negative

• Series B treatment pending accounting determination for equity classification
• Panel review may still find Nasdaq stockholders' equity noncompliant
• Preferred issuance could complicate future capital structure and liquidity

News Market Reaction – LNAI

+1.47%

21 alerts

+1.47% Session close to close

+6.7% Peak Tracked

-38.0% Trough Tracked

$11.77M Market Cap

0.3x Rel. Volume

In the May 4 session, LNAI gained 1.47%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.7% during that session. Argus tracked a trough of -38.0% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a $20 million preferred issuance used to acquire CNS delivery and neurothe...

Analysis

This announcement details a $20 million preferred issuance used to acquire CNS delivery and neurotherapeutic IP, while also supporting Nasdaq stockholders’ equity compliance efforts above the $2.5 million threshold under Rule 5550(b)(1). It builds on prior CNS and AI initiatives, including a BBB delivery acquisition and defense collaborations. Investors may watch for the Nasdaq Panel’s decision, progress in integrating the new BBB and nose-to-brain technologies, and any follow-on partnerships or non-dilutive funding.

Key Figures

Preferred equity issuance: $20 million Series B Preferred Stated Value: $20,000,000 Nasdaq equity minimum: $2.5 million +4 more

7 metrics

Preferred equity issuance $20 million Preferred equity issued to acquire CNS IP assets

Series B Preferred Stated Value $20,000,000 Aggregate Stated Value of Series B Preferred Stock issued May 1, 2026

Nasdaq equity minimum $2.5 million Minimum stockholders’ equity required by Nasdaq Listing Rule 5550(b)(1)

Listing rule Rule 5550(b)(1) Nasdaq Stockholders’ Equity Rule referenced for compliance

Rule reference Bid Price Rule Ongoing Nasdaq bid-price compliance review by Panel

Effective date May 1, 2026 Date Company completed the Merger and issued Series B Preferred

Transaction amount (prior deal) $20.0 million Size of March 26, 2026 strategic BBB delivery acquisition

Previous Acquisition Reports

1 past event · Latest: Mar 26 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 26	CNS platform acquisition	Positive	+22.9%	Acquisition of BBB delivery platform and CNS Alzheimer’s assets via $20M deal.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The only prior acquisition-tagged event over the past six months saw a strongly positive price reaction of 22.94% the next day.

Recent Company History

Over recent months, Lunai Bioworks reported several AI- and CNS-focused developments, including a U.S. patent on its core AI architecture, launch of the Pathfinder chemical defense consortium, and a multi-year revenue-generating defense collaboration via BioSymetrics. It also executed a $20.0M acquisition of a BBB delivery platform and CNS Alzheimer’s assets, which drew a 22.94% next-day gain. The current acquisition-related transaction continues this strategy of expanding CNS delivery and therapeutic capabilities while addressing Nasdaq compliance considerations.

Key Terms

blood-brain barrier, BBB, nose-to-brain, 505(b)(2), +3 more

7 terms

blood-brain barrier medical

"where the blood-brain barrier (BBB) can restrict therapeutic access to the brain"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

BBB medical

"where the blood-brain barrier (BBB) can restrict therapeutic access"

bbb is a mid-level credit rating that signals an issuer or bond is financially stable but more vulnerable to adverse conditions than higher-rated peers. Think of it like a middle-of-the-road safety score for a car: it’s acceptable for everyday use but not the safest option in extreme conditions. For investors, a bbb rating matters because it influences borrowing costs, expected returns and portfolio rules about how much risk is acceptable, with lower ratings typically offering higher yields to compensate for greater risk.

nose-to-brain medical

"a BBB-crossing prodrug system and a nose-to-brain (N2B) delivery pathway"

A nose-to-brain approach delivers medicines through the nose directly toward the brain by using nerve pathways that bypass the bloodstream and the brain’s protective barrier. Think of it as a back door into the brain that can let drugs act faster, with smaller doses and fewer whole-body side effects. Investors watch this route because it can enable new treatments for brain disorders, change clinical trial outcomes, and affect regulatory and commercial prospects.

505(b)(2) regulatory

"505(b)(2) development pathways, and CNS-targeted biodefense and countermeasure"

A 505(b)(2) is an FDA drug approval pathway that lets a company win approval by relying partly on existing studies or published data instead of doing all new clinical trials. Think of it like building a renovated house using the original foundation: it can be faster and less costly than a full new-drug route, reducing development risk and expense. Investors care because it can speed market entry, lower capital needs, and offer opportunities for exclusivity or competitive advantage.

central nervous system medical

"expanding the Company's central nervous system (CNS) platform with complementary"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

Series B Preferred Stock financial

"issued the Series B Preferred Stock having an aggregate Stated Value of $20,000,000"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Nasdaq Stockholders' Equity Rule regulatory

"principal transaction undertaken by the Company to achieve compliance with the Nasdaq Stockholders' Equity Rule"

A NASDAQ stockholders' equity rule sets the minimum net worth a company must report—assets minus liabilities—to qualify for or remain on the NASDAQ exchange. It matters to investors because falling below that threshold can trigger warnings, trading restrictions, or delisting, much like a bank requiring a minimum balance to keep an account open; such actions often reduce a stock’s liquidity and can sharply lower its market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications

SACRAMENTO, Calif., May 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the Company's central nervous system (CNS) platform with complementary neurotherapeutic compounds and delivery technologies. The acquired portfolio is designed to address a key limitation in neurological disease treatment, including Alzheimer's disease, where the blood-brain barrier (BBB) can restrict therapeutic access to the brain. The expanded intellectual property portfolio introduces complementary CNS delivery technologies and multi-agent, combinatorial therapeutic approaches, which will be integrated into Lunai Bioworks IP, Inc., a wholly owned subsidiary, broadening the Company's growing platform of neurological disease and biodefense applications.

The transaction integrates two distinct CNS delivery approaches into Lunai's platform: a BBB-crossing prodrug system and a nose-to-brain (N2B) delivery pathway that bypasses the BBB via olfactory and trigeminal routes. Together, these approaches are intended to support both individual and combination therapies, align with Lunai's AI-driven patient stratification strategy, expand potential applications across neurological disease, 505(b)(2) development pathways, and CNS-targeted biodefense and countermeasure programs, and position Lunai for potential partnership, licensing, and non-dilutive funding opportunities.

The acquired intellectual property expands Lunai's ability to connect therapeutic discovery with delivery, supporting a more integrated approach to CNS drug development. By pairing compound design with delivery optimization, the Company is advancing a framework aimed at increasing drug concentration in the brain while reducing systemic exposure. This approach addresses both challenges by combining novel neurotherapeutic compounds with complementary delivery technologies, improving CNS access and enabling multi-agent, combinatorial strategies. Together, the portfolio strengthens Lunai's ability not only to deliver therapeutics to the brain, but to develop and deploy both single-agent and combination therapies that target distinct aspects of disease biology. This approach may be applicable across multiple neurological indications as well as in settings requiring rapid CNS access.

Lunai's Augusta platform is designed to stratify patient populations based on underlying biological drivers rather than traditional disease classifications. The integration of these assets is expected to support the development of targeted therapeutic combinations matched to specific patient subgroups, including in the context of neurological disease and acute toxic or environmental exposures. This combined approach is intended to improve the efficiency of candidate selection and advancement.

The combined platform is also expected to support multiple regulatory pathways, including potential 505(b)(2) opportunities for reformulated or repurposed therapeutics. These pathways may enable more efficient development timelines and reduced clinical risk relative to traditional de novo drug development programs.

In addition, the expanded intellectual property portfolio is expected to strengthen Lunai's role in biodefense-related initiatives, including its Pathfinder program, by increasing its capacity to evaluate and deploy CNS-targeted countermeasures. This includes the potential use of established pharmacological agents in combination with alternative delivery approaches designed for rapid administration and central nervous system access following chemical or environmental exposures.

"This transaction brings together complementary CNS delivery approaches that address one of the most persistent challenges in neurological drug development," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "By integrating these technologies with our existing platform, we are expanding our ability to develop and deliver targeted therapies, while also opening additional pathways for partnership, licensing, and non-dilutive funding."

On May 1, 2026, the Company completed the Merger and issued the Series B Preferred Stock having an aggregate Stated Value of $20,000,000 to the Holders. The Merger and the related issuance of the Series B Preferred Stock is the principal transaction undertaken by the Company to achieve compliance with the Nasdaq Stockholders' Equity Rule and the Company will determine and disclose the equity treatment of the Series B Preferred Stock in accordance with applicable accounting standards. After giving effect to the Merger, the issuance of the Series B Preferred Stock, and based on the Company's preliminary accounting and fair-value analysis, the Company believes its stockholders' equity exceeds the $2.5 million minimum required by Nasdaq Listing Rule 5550(b)(1). The Company is awaiting the Panel's formal determination of compliance with the Stockholder's Equity Rule. There can be no assurance that the Panel will determine that the Company has satisfied the Stockholders' Equity Rule, and any such determination by the Panel is subject to the Panel's continuing review of the Company's disclosures, financial condition and progress toward compliance with the Bid Price Rule. If the Panel determines that the Company has not satisfied the conditions set forth in the Panel's decision (as so extended), Nasdaq may take further action to delist the Company's common stock from The Nasdaq Capital Market.

About Lunai Bioworks, Inc.
Lunai Bioworks (NASDAQ: LNAI) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform. Lunai combines clinical data, machine learning, and in vivo validation to identify disease biology and develop precision therapeutics. Lunai is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements regarding the expected benefits of the transaction, potential applications of the acquired intellectual property, development timelines, regulatory pathways, and potential partnership, licensing, or funding opportunities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Lunai undertakes no obligation to update these statements except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-completes-20-million-preferred-issuance-to-acquire-cns-delivery-and-neurotherapeutic-ip-302761369.html

SOURCE Lunai Bioworks Inc.

FAQ

What did Lunai Bioworks (LNAI) announce on May 4, 2026 about the $20 million transaction?

Lunai Bioworks completed a $20.0 million Series B preferred issuance to acquire CNS delivery and neurotherapeutic IP. According to Lunai Bioworks, the assets add a BBB prodrug and a nose-to-brain delivery pathway to its CNS platform and were placed into a wholly owned IP subsidiary.

How will the acquired IP affect Lunai Bioworks' Alzheimer’s and CNS programs (LNAI)?

The acquisition adds delivery technologies intended to increase brain drug concentration while reducing systemic exposure. According to Lunai Bioworks, the portfolio supports single-agent and combination strategies and aligns with its Augusta patient stratification platform for targeted subgroups.

Does the $20 million preferred issuance resolve Lunai Bioworks' Nasdaq equity compliance (LNAI)?

The company believes stockholders' equity exceeds the $2.5 million Nasdaq minimum after the transaction. According to Lunai Bioworks, it is awaiting the Nasdaq Panel's formal determination and stated no assurance the Panel will confirm compliance.

What regulatory development pathways does the Lunai IP acquisition enable for LNAI programs?

The expanded IP portfolio is expected to support potential 505(b)(2) pathways for reformulated or repurposed drugs. According to Lunai Bioworks, these pathways may allow more efficient timelines and reduced clinical risk versus de novo development.

How might the new IP impact Lunai Bioworks' biodefense and countermeasure efforts (LNAI)?

The assets are intended to strengthen CNS-targeted countermeasure capabilities for rapid central nervous system access. According to Lunai Bioworks, this includes evaluating established agents with alternative delivery approaches for acute toxic or environmental exposures.